Eli Lilly Long Term Debt 2010-2023 | LLY

Eli Lilly long term debt from 2010 to 2023. Long term debt can be defined as the sum of all long term debt fields.
  • Eli Lilly long term debt for the quarter ending December 31, 2023 was $18.321B, a 24.31% increase year-over-year.
  • Eli Lilly long term debt for 2023 was $18.321B, a 24.31% increase from 2022.
  • Eli Lilly long term debt for 2022 was $14.738B, a 3.97% decline from 2021.
  • Eli Lilly long term debt for 2021 was $15.346B, a 7.48% decline from 2020.
Eli Lilly Annual Long Term Debt
(Millions of US $)
2023 $18,321
2022 $14,738
2021 $15,346
2020 $16,587
2019 $13,818
2018 $9,196
2017 $9,941
2016 $8,368
2015 $7,972
2014 $5,333
2013 $4,200
2012 $5,519
2011 $5,465
2010 $6,771
2009 $6,635
Eli Lilly Quarterly Long Term Debt
(Millions of US $)
2023-12-31 $18,321
2023-09-30 $17,924
2023-06-30 $18,158
2023-03-31 $18,881
2022-12-31 $14,738
2022-09-30 $14,144
2022-06-30 $14,692
2022-03-31 $15,153
2021-12-31 $15,346
2021-09-30 $15,522
2021-06-30 $14,737
2021-03-31 $16,200
2020-12-31 $16,587
2020-09-30 $16,335
2020-06-30 $15,064
2020-03-31 $13,982
2019-12-31 $13,818
2019-09-30 $13,662
2019-06-30 $13,718
2019-03-31 $13,610
2018-12-31 $9,196
2018-09-30 $11,675
2018-06-30 $9,171
2018-03-31 $9,394
2017-12-31 $9,941
2017-09-30 $9,927
2017-06-30 $9,868
2017-03-31 $7,638
2016-12-31 $8,368
2016-09-30 $8,707
2016-06-30 $8,686
2016-03-31 $7,478
2015-12-31 $7,972
2015-09-30 $8,070
2015-06-30 $7,989
2015-03-31 $7,415
2014-12-31 $5,333
2014-09-30 $5,293
2014-06-30 $5,301
2014-03-31 $5,255
2013-12-31 $4,200
2013-09-30 $4,264
2013-06-30 $4,291
2013-03-31 $4,432
2012-12-31 $5,519
2012-09-30 $5,511
2012-06-30 $5,500
2012-03-31 $5,403
2011-12-31 $5,465
2011-09-30 $5,451
2011-06-30 $5,200
2011-03-31 $5,132
2010-12-31 $6,771
2010-09-30 $6,982
2010-06-30 $6,862
2010-03-31 $6,661
2009-12-31 $6,635
2009-09-30 $6,770
2009-06-30 $6,688
2009-03-31 $6,871
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $731.812B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.87
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01